| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -99,111 | -108,039 | -103,433 | -201,309 |
| Gain on sale of contingent payments | NaN | 0 | 0 | NaN |
| Depreciation and amortization | 1,363 | 1,266 | 1,374 | 2,537 |
| Loss (gain) on disposal of property and equipment | NaN | 299 | -299 | -5 |
| Stock-based compensation expense | 15,541 | 14,124 | 12,377 | 26,051 |
| Net accretion of discount on marketable securities | 1,144 | 1,753 | 1,674 | 3,768 |
| Non-cash operating lease expense | 3,258 | 3,196 | 3,135 | 6,094 |
| Expense associated with license agreement | NaN | 0 | 0 | 10,000 |
| Realized gain on investments | 28 | 118 | -2 | 2 |
| Milestone payment from gain on sale of oncology business | NaN | 0 | 0 | NaN |
| Accounts receivable, net | 5,555 | 5,548 | 43 | 877 |
| Inventory | 2,167 | 886 | 1,186 | 3,232 |
| Prepaid expenses and other current and non-current assets | 2,456 | 945 | -1,519 | 3,746 |
| Accounts payable | -4,993 | -1,145 | 1,807 | 1,084 |
| Accrued expenses and other current liabilities | -19,166 | 8,242 | 1,928 | -11,572 |
| Other non-current liabilities | NaN | NaN | -11 | -779 |
| Income taxes payable | 0 | 0 | 0 | -871 |
| Operating lease liabilities | -4,462 | -4,308 | -4,245 | -8,228 |
| Other liabilities | NaN | -790 | NaN | NaN |
| Net cash used in operating activities | -118,920 | -96,213 | -88,151 | -188,613 |
| Proceeds from sale of equipment | NaN | 0 | 0 | 0 |
| Purchases of marketable securities | 148,182 | 161,078 | 174,981 | 305,700 |
| Proceeds from maturities and sales of marketable securities | 290,263 | 252,274 | 272,091 | 508,894 |
| Proceeds from sale of contingent payments | NaN | 0 | 0 | NaN |
| Proceeds from milestone payment from gain on sale of oncology business | NaN | 0 | 0 | NaN |
| Payments associated with license agreement | NaN | 0 | 0 | 10,000 |
| Purchases of property and equipment | 769 | 1,120 | 1,555 | 1,641 |
| Net cash provided by investing activities | 141,312 | 90,076 | 95,555 | 191,553 |
| Net proceeds from stock option exercises and employee stock purchase plan | 2,078 | 2,557 | 4,435 | 1,684 |
| Net cash provided by financing activities | 2,078 | 2,557 | 4,435 | 1,684 |
| Net change in cash and cash equivalents | 24,470 | -3,580 | 11,839 | 4,624 |
| Cash and cash equivalents at beginning of the period | 89,130 | 92,710 | 76,247 | NaN |
| Cash and cash equivalents at end of the period | 113,600 | 89,130 | 92,710 | NaN |
AGIOS PHARMACEUTICALS, INC. (AGIO)
AGIOS PHARMACEUTICALS, INC. (AGIO)